The alliance will combine CordenPharma’s proprietary Lipid NanoParticle (LNP) technology and GMP manufacturing expertise with pHLIP’s proprietary pH (Low) Insertion Peptide (pHLIP) targeted delivery technology and drug development expertise to formulate coated LNPs for use by biopharmaceutical companies seeking to deliver mRNA-based and gene therapy payloads.

Applications for the technology are in cancer, inflammation, genetic diseases, and mRNA vaccines. The novel pHLIP-LNP platform may enhance the commercial viability and success of many pioneering RNA, DNA, and CRISPR therapies.

Michael Quirmbach, CordenPharma CEO & President, commented “CordenPharma is proud to participate in this alliance with pHLIP, as it represents a great synergy of cutting-edge technology and lipid, peptide, conjugate and LNP expertise which brings a potentially game-changing delivery platform to the LNP-based drug development field. Our collaboration allows access to effective, precisely targeted LNP delivery of RNA, DNA, and gene therapy payloads across various important therapeutic indications, with an ultimately profound effect on saving the lives of patients.”

The alliance will also enable CordenPharma and pHLIP to develop and manufacture small molecule drug payloads directly conjugated with peptides for biopharmaceutical companies. CordenPharma serves as the CDMO supplier in the GMP manufacture of pHLIP peptides and (pHLIP) drug conjugates and the new alliance further builds upon their collaborative efforts in this important field.

Yana Reshetnyak, pHLIP Co-Founder, CEO & President, stated “CordenPharma’s expertise in formulating and manufacturing LNPs and pHLIP peptides makes them our ideal partner for this important venture. The University of Rhode Island will continue to be our partner in the development of the pHLIP platform technology and pHLIP therapeutics. The pHLIP-LNP delivery platform technology holds tremendous potential for further unlocking the promise of the medical uses of RNA, DNA and CRISPR therapeutics.